(FTV) Fortive - Overview
Stock: Instruments, Software, Sensors, Sterilizers, Trackers
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.54% |
| Yield on Cost 5y | 0.66% |
| Yield CAGR 5y | 4.19% |
| Payout Consistency | 98.6% |
| Payout Ratio | 8.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 23.5% |
| Relative Tail Risk | -5.82% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.02 |
| Alpha | -13.93 |
| Character TTM | |
|---|---|
| Beta | 0.934 |
| Beta Downside | 1.137 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.01% |
| CAGR/Max DD | 0.21 |
Description: FTV Fortive January 03, 2026
Fortive Corp (NYSE:FTV) is a diversified industrial-technology company that designs, manufactures and markets products, software and services across the United States, China and other global markets. It operates through two primary segments: Intelligent Operating Solutions (IOS) and Advanced Healthcare Solutions (AHS).
The IOS segment delivers advanced instrumentation, test-and-measurement equipment, lifecycle-management software and connected-worker safety tools for manufacturers, process industries, utilities, communications and electronics firms. Key brands include ACCRUENT, FLUKE, GORDIAN, INDUSTRIAL SCIENTIFIC, INTELEX, PRUFTECHNIK and SERVICECHANNEL.
The AHS segment focuses on critical workflow solutions for the medical-device and clinical-care ecosystem, offering instrument sterilization, tracking, cell-therapy hardware, biomedical test tools, radiation-safety monitoring and end-to-end clinical productivity software. Prominent brands are ASP, CENSIS, CENSITRAC, EVOTECH, FLUKE BIOMEDICAL, INVETECH, LANDAUER, PROVATION, RAYSAFE and STERRAD.
Recent financials (FY 2023) show revenue of roughly $5.6 billion, up 4 % YoY, with an adjusted EBITDA margin of ~15 % and free cash flow generation of $550 million, reflecting steady demand for automation-driven solutions and resilient healthcare-equipment spending despite macro-uncertainty.
Key economic drivers for Fortive include the ongoing industrial automation wave, which is projected to grow at a 6-7 % CAGR through 2028, and the expanding global market for sterile processing and cell-therapy equipment, a segment that is expected to outpace overall healthcare-equipment growth by 2-3 pp annually.
Investors should watch the company’s ability to capture share-of-wallet in the “connected worker” safety market (estimated $12 billion TAM) and its progress on high-margin software-as-a-service contracts, which historically deliver >20 % recurring-revenue growth.
For a deeper quantitative view, consider exploring ValueRay’s proprietary valuation metrics on Fortive to assess whether the current price reflects its long-term growth potential.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 579.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -2.79 > 1.0 |
| NWC/Revenue: -12.46% < 20% (prev 5.68%; Δ -18.14% < -1%) |
| CFO/TA 0.15 > 3% & CFO 1.80b > Net Income 579.2m |
| Net Debt (2.83b) to EBITDA (1.17b): 2.42 < 3 |
| Current Ratio: 0.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (319.4m) vs 12m ago -8.22% < -2% |
| Gross Margin: 60.96% > 18% (prev 0.60%; Δ 6036 % > 0.5%) |
| Asset Turnover: 35.77% > 50% (prev 36.62%; Δ -0.85% > 0%) |
| Interest Coverage Ratio: 5.13 > 6 (EBITDA TTM 1.17b / Interest Expense TTM 120.5m) |
Altman Z'' 2.53
| A: -0.05 (Total Current Assets 1.61b - Total Current Liabilities 2.25b) / Total Assets 11.74b |
| B: 0.46 (Retained Earnings 5.43b / Total Assets 11.74b) |
| C: 0.04 (EBIT TTM 617.9m / Avg Total Assets 14.38b) |
| D: 1.04 (Book Value of Equity 5.47b / Total Liabilities 5.28b) |
| Altman-Z'' Score: 2.53 = A |
Beneish M -3.36
| DSRI: 0.88 (Receivables 683.6m/945.4m, Revenue 5.14b/6.23b) |
| GMI: 0.98 (GM 60.96% / 59.87%) |
| AQI: 1.02 (AQ_t 0.84 / AQ_t-1 0.82) |
| SGI: 0.83 (Revenue 5.14b / 6.23b) |
| TATA: -0.10 (NI 579.2m - CFO 1.80b) / TA 11.74b) |
| Beneish M-Score: -3.36 (Cap -4..+1) = AA |
What is the price of FTV shares?
Over the past week, the price has changed by +13.84%, over one month by +8.42%, over three months by +17.83% and over the past year by +0.51%.
Is FTV a buy, sell or hold?
- StrongBuy: 6
- Buy: 5
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the FTV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 59.9 | -0.3% |
| Analysts Target Price | 59.9 | -0.3% |
| ValueRay Target Price | 61.3 | 1.9% |
FTV Fundamental Data Overview February 07, 2026
P/E Forward = 21.2766
P/S = 4.5972
P/B = 2.9594
P/EG = 1.2896
Revenue TTM = 5.14b USD
EBIT TTM = 617.9m USD
EBITDA TTM = 1.17b USD
Long Term Debt = 2.31b USD (from longTermDebt, last quarter)
Short Term Debt = 899.5m USD (from shortTermDebt, last quarter)
Debt = 3.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.83b USD (from netDebt column, last quarter)
Enterprise Value = 21.95b USD (19.12b + Debt 3.21b - CCE 375.5m)
Interest Coverage Ratio = 5.13 (Ebit TTM 617.9m / Interest Expense TTM 120.5m)
EV/FCF = 34.16x (Enterprise Value 21.95b / FCF TTM 642.6m)
FCF Yield = 2.93% (FCF TTM 642.6m / Enterprise Value 21.95b)
FCF Margin = 12.50% (FCF TTM 642.6m / Revenue TTM 5.14b)
Net Margin = 11.26% (Net Income TTM 579.2m / Revenue TTM 5.14b)
Gross Margin = 60.96% ((Revenue TTM 5.14b - Cost of Revenue TTM 2.01b) / Revenue TTM)
Gross Margin QoQ = 63.15% (prev 63.21%)
Tobins Q-Ratio = 1.87 (Enterprise Value 21.95b / Total Assets 11.74b)
Interest Expense / Debt = 0.97% (Interest Expense 31.0m / Debt 3.21b)
Taxrate = 17.65% (39.8m / 225.5m)
NOPAT = 508.8m (EBIT 617.9m * (1 - 17.65%))
Current Ratio = 0.71 (Total Current Assets 1.61b / Total Current Liabilities 2.25b)
Debt / Equity = 0.50 (Debt 3.21b / totalStockholderEquity, last quarter 6.45b)
Debt / EBITDA = 2.42 (Net Debt 2.83b / EBITDA 1.17b)
Debt / FCF = 4.40 (Net Debt 2.83b / FCF TTM 642.6m)
Total Stockholder Equity = 8.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.03% (Net Income 579.2m / Total Assets 11.74b)
RoE = 6.90% (Net Income TTM 579.2m / Total Stockholder Equity 8.39b)
RoCE = 5.77% (EBIT 617.9m / Capital Employed (Equity 8.39b + L.T.Debt 2.31b))
RoIC = 3.90% (NOPAT 508.8m / Invested Capital 13.03b)
WACC = 8.13% (E(19.12b)/V(22.33b) * Re(9.36%) + D(3.21b)/V(22.33b) * Rd(0.97%) * (1-Tc(0.18)))
Discount Rate = 9.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.08%
[DCF Debug] Terminal Value 78.99% ; FCFF base≈948.1m ; Y1≈1.04b ; Y5≈1.34b
Fair Price DCF = 62.95 (EV 22.56b - Net Debt 2.83b = Equity 19.73b / Shares 313.4m; r=8.13% [WACC]; 5y FCF grow 11.56% → 2.90% )
EPS Correlation: -29.42 | EPS CAGR: 6.93% | SUE: 0.58 | # QB: 0
Revenue Correlation: -38.58 | Revenue CAGR: -5.29% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.65 | Chg30d=+0.023 | Revisions Net=+0 | Analysts=8
EPS current Year (2026-12-31): EPS=2.95 | Chg30d=+0.095 | Revisions Net=-5 | Growth EPS=+8.8% | Growth Revenue=+3.5%
EPS next Year (2027-12-31): EPS=3.12 | Chg30d=+0.069 | Revisions Net=-3 | Growth EPS=+6.0% | Growth Revenue=+3.6%